Who is sponsoring NCT04374721?

NCT04374721 is sponsored by University of Roma La Sapienza.

What drugs are being tested in NCT04374721?

Interventions in NCT04374721: circadian gene expression evaluation.

What condition does NCT04374721 study?

NCT04374721 studies Cushing Syndrome, Adrenal Insufficiency, Cushing Disease, Addison Disease.

Is NCT04374721 still recruiting?

NCT04374721 is currently status unknown. Last updated 30 November 2022.

Last reviewed 2022-11-30 · How we verify

NCT04374721: CHROnOS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders

Status unknown NA Last updated 30 November 2022

What this trial tests

NA trial testing circadian gene expression evaluation in Cushing Syndrome in 44 participants. Status unknown.

Timeline

4 July 2018

Primary endpoint
1 June 2023

1 December 2023

Quick facts

Lead sponsor	University of Roma La Sapienza
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	44
Start date	4 July 2018
Primary completion	1 June 2023
Estimated completion	1 December 2023
Sites	1 location across Italy

Drugs / interventions tested

circadian gene expression evaluation

Conditions studied

Cushing Syndrome — all drugs for Cushing Syndrome →
Adrenal Insufficiency — all drugs for Adrenal Insufficiency →
Cushing Disease — all drugs for Cushing Disease →
Addison Disease — all drugs for Addison Disease →

Sponsor

University of Roma La Sapienza

Who can join

Adults 18 to 80, any sex, with Cushing Syndrome or Adrenal Insufficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicentric, prospective, intervention study on circadian genes expression in peripheral blood mononuclear cells as biomarkers of circadian rhythm derangement in patients affected by alterations of endogenous glucocorticoids secretion (Cushing's Syndrome during active phase, treatment and under remission and newly or on established glucocorticoid replacement therapy adrenal insufficiency)

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Chronotherapy With Once-Daily Osilodrostat Improves Cortisol Rhythm, Quality of Life, and Sleep in Cushing's Syndrome.
Ferrari D, Bonaventura I, Simeoli C, Tomaselli A, et al · · 2025 · cited 18× · PMID 40172910 · DOI 10.1210/clinem/dgaf206
Circadian clock disruption impairs immune oscillation in chronic endogenous hypercortisolism: a multi-level analysis from a multicentre clinical trial.
Hasenmajer V, Sbardella E, Sciarra F, Simeoli C, et al · · 2024 · cited 12× · PMID 39612654 · DOI 10.1016/j.ebiom.2024.105462

Verify or expand the search:

Other recruiting trials for Cushing Syndrome

Currently open trials in the same condition.

NCT07168122 — Establishment and Clinical Application of Reference Intervals of Salivary Cortisol · recruiting
NCT06635629 — Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome · Phase 2 · recruiting
NCT06573723 — Institutional Registry of Rare Diseases · recruiting
NCT06250699 — A Single Center Randomized Controlled Study on the Promotion of Rapid Recovery · NA · recruiting
NCT05911620 — Evaluation of the Severity of Hepatic Fibrosis by Magnetic Resonance Elastography in the Diagnosis of Endogenous Hyperco · NA · recruiting

Other University of Roma La Sapienza trials

Trials by the same sponsor.

NCT07485023 — Oral Versus Intravenous Iron for Anemia Diagnosed After 34 Weeks of Gestation · NA · not yet recruiting
NCT07305519 — The Combined Effect of Magnesium, Palmitoylethanolamide, High-Molecular-weight Hyaluronic Acid, Vitamin B6, and Vitamin · NA · not yet recruiting
NCT07520968 — ABX Versus CHX in NSPT: a RCT · NA · active not recruiting
NCT07109596 — Integration of Clinical, Biological and Psycho-social Variables for a Gender-sensitive Frailty Prediction · recruiting
NCT07490574 — Trial of Underwater Versus Gas-Insufflation Colorectal Endoscopic Submucosal DisseEtion · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04374721 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Roma La Sapienza
Last refreshed: 30 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04374721.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing